Lung Transplant Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Transplant, including details on risks, prognosis, procedure, surgery, organ donation.

A case series of drotrecogin alfa (activated) in lung transplant recipients.

Daniels TL, Dummer JS, Bernard GR, Milstone AP

Division of Infectious Diseases, Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA. titus.daniels@vanderbilt.edu

Severe sepsis in lung transplant recipients is a challenging problem and carries a high mortality. Recombinant human activated protein C (drotrecogin alfa [activated]) has been approved for use in patients with severe sepsis. Its use has been shown to be safe and impart a survival advantage. However, the safety of drotrecogin alfa activated has not been evaluated in lung transplant recipients. We report for the first time on the use of drotrecogin alfa activated in six lung transplant recipients. Clinical trials are warranted to further evaluate the use of drotrecogin alfa activated in transplant recipients.

Published 23 June 2006 in Transplantation, 81(12): 1739-42.
Full-text of this article is available online (may require subscription).

© 2005-2008 Lung Transplant Research Today. All Rights Reserved.